Zydus partners with Formycon for Keytruda biosimilar in US, Canada

• Zydus Life's unit partnered with Formycon AG for exclusive licensing and supply of FYB206, a Keytruda biosimilar.
• The agreement covers the US and Canada, with Formycon developing/supplying and Zydus commercializing the product.
• The partnership aims to make affordable and accessible immunotherapy available to patients.
• A biologics licence application for FYB206 is expected to be submitted to the US FDA soon.
• This venture marks Zydus' entry into the North American biosimilar market with an immunotherapy product.

Why It Matters: This deal makes a vital cancer immunotherapy drug more affordable and accessible.